Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
PierFranco Conte(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Michele Aieta(Centro di Riferimento Oncologico della Basilicata), Eugenia Bajardi(La Maddalena), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Anita Rimanti(Azienda Ospedaliera Carlo Poma), Roberto D’Amico(University of Modena and Reggio Emilia), Filippo Giovanardi, Claudio Zamagni(Policlinico S.Orsola-Malpighi), Michela Donadio(Azienda Ospedaliero Universitaria San Giovanni Battista), Gabriella Moretti(Istituti di Ricovero e Cura a Carattere Scientifico), Roberta Maltoni(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), P. Pronzato(Accademia Nazionale dei Lincei), Alessandra Beano(Presidio Ospedaliero), Sara Balduzzi(Dutch Cancer Society), Silvio Danese(IRCCS Ospedale San Raffaele), Giancarlo Bisagni, Roberto Vicini, Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Luigi Cavanna(University of Pavia), Francesco Giotta(Istituto Tumori Bari), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Antonella Ferro(Ospedale Santa Chiara), Antonio Russo(University of Palermo), Vittorio Gebbia(La Maddalena), Laura Lombardo(Istituto delle Scienze Neurologiche di Bologna), Alessio Schirone, A. Molino(University of Verona), Laura Amaducci(Ospedale degli Infermi)
Cited by 157
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k